-
SCENIC Study for IPF-Related Cough
A popular topic among our forum members is the nagging, dry cough that often accompanies a diagnosis of idiopathic pulmonary fibrosis (IPF). For some patients, this cough can drastically lower their quality of life and contribute to muscle pain, fatigue and even cause difficulty in social situations when others assume the cough is contagious. While there are many unstudied theories that certain medications suppress or reduce the cough, such as a Gabepentin, wouldn’t it be great if there was scientific trial through a credible biopharmaceutical company dedicated to trying to treat the IPF cough?
While I was attending the PFF Summit in San Antonio last weekend, I was privileged to spend time with some of the staff from Respivant. This biopharmaceutical company has launched a study, currently in phase 2, called the Scenic study to address the IPF-related dry cough. They are currently recruiting for more participants, which you can read more on HERE or by calling: 1-800-993-9964.
Even more information can be found here.
If you struggle with the pesky IPF-related cough, and want more information please feel free to connect with me directly or contact Respivant. They have been extremely supportive, kind and are obviously dedicated to the effectiveness and success of this study. I am so happy to be able to share it with all of you!
Charlene.
Log in to reply.